Physician profile
Naznin Khan
NPI 1891926853
$2,842.92
in general payments reported to CMS, 2019-2025
18 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $282 · 2021: $378 · 2022: $259 · 2023: $347 · 2024: $1,099 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615 · Education: $73.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.44 |
| Education | $73.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $477.24 | 2019-2023 | Bexsero, Arexvy, Shingrix |
| Exact Sciences Corporation | $416.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $351.20 | 2019-2024 | Verquvo, Steglatro, Vaxneuvance |
| Novo Nordisk INC | $316.79 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $257.28 | 2024 | Repatha, Otezla |
| Lilly USA, LLC | $183.81 | 2022-2025 | Mounjaro, Zepbound |
| Renalytix Ai, INC. | $157.93 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.76 | 2020-2024 | Jardiance |
| Pfizer INC. | $137.55 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $74.98 | 2021-2024 | Farxiga |
| Dexcom, INC. | $73.18 | 2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $54.24 | 2024-2025 | Zoryve |
| Global Blood Therapeutics, INC. | $49.12 | 2021-2022 | |
| Sanofi Pasteur INC. | $45.43 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $39.98 | 2024-2025 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $21.30 | 2022 | |
| Shield Therapeutics INC | $20.93 | 2024 | |
| Amag Pharmaceuticals, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naznin Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.